Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.

Journal of the International AIDS Society - 1 Nov 2017

Coetzer Mia, Ledingham Lauren, Diero Lameck, Kemboi Emmanuel, Orido Millicent, Kantor Rami

Abstract excerpt

INTRODUCTION: Failure of protease-inhibitor (PI)-based second-line antiretroviral therapy (ART) with medication adherence but no protease drug resistance mutations (DRMs) is not well understood. This study investigated the involvement of gp41 and gag as alternative mechanisms, not captured by conventional resistance testing and particularly relevant in resource-limited settings where third-line ART is limited....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Motifs
Share to gag Gene Products, Human Immunodeficiency Virus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 29098809
DOI: 10.1002/jia2.25024
PMCID: PMC5810327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.PMID 29098809Read ↗

Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy.Semantic proximity Read ↗

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.Semantic proximity Read ↗

Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.Semantic proximity Read ↗

HIV-1 Envelope Glycoprotein Amino Acids Signatures Associated with Clade B Transmitted/Founder and Recent Viruses.Semantic proximity Read ↗

Evaluation of C-terminal p7 (NC)-p6 Gag genetic variants among HIV-1 non-B subtypes in a subset of Cameroonian patientsSemantic proximity Read ↗

HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.Semantic proximity Read ↗

Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease InhibitorsSemantic proximity Read ↗

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.Semantic proximity Read ↗

Population-specific evolution of HIV Gag epitopes in genetically diverged patients.Semantic proximity Read ↗

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.Semantic proximity Read ↗

Partial HIV C2V3 envelope sequence analysis reveals association of coreceptor tropism, envelope glycosylation and viral genotypic variability among Kenyan patients on HAART.Semantic proximity Read ↗

Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.